X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla vs Peers - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Aug 13, 2004

    Cipla vs Peers

    Cipla has seen a lot of activity over the past one month, and the stock has gained about 15% since July 2004. In the same period, the other two pharma giants, Dr Reddy's and Ranbaxy have gained only 3% and 6% respectively. So what has caught the investor's fancy with regard to Cipla? Let's find out.

    Let's consider various business aspects of these three companies.

    From the chart above, one can say that Cipla has outperformed both its competitors with the consistency of its growth over a period of time. There was a jump in Cipla's sales in 4QFY04, which was basically led by a significant surge in the bulk drug sales (98% YoY). By increasing the exports business, company has managed to deliver growth. That apart, Cipla has done better than any other player in the domestic markets too, with aggressive product launches in last two years. This strategy is different from the other Indian pharma companies, which are trying to create big but fewer brands, so as to leverage on brand equity post 2005.

    Cipla is currently the largest pharma company in domestic retail market according to ORG-MARG survey. However, the other two companies have shown a different picture on growth front. While the growth of Ranbaxy in the aforesaid quarters was fairly consistent, as the drop in sales in US market was compensated by the increase in sales in the European market. Dr Reddy's concentration on Para IV filings has brought down the sales, as it has not got any positive approvals in last two and a half years on that front. Also, increasing competition in generics has brought down the realizations, which has lowered the growth in the revenues.

    On margins front too, Cipla must get full marks for the consistency. While margins of the company are less compared to Ranbaxy, it is the consistency in the margin, which is commendable. Although, it is acknowledged by the industry that Cipla is one of the most efficient producer of drugs in the country, the business mix and sales mix is such that the margins are lower compared to Ranbaxy and Dr Reddy's. While the other two companies enjoy higher margins from generics business in the regulated markets, Cipla is focussed on formulation sales in the unregulated markets of India, Middle East, Africa and Eastern Europe and CIS countries.

    While margins of Dr Reddy's have been badly beaten for the period under review due to decrease in sales from US generics and increase in R&D expenses, the margins of Ranbaxy have remained steady. The margins of Dr Reddy's and Ranbaxy are dependent on their performance in the highly competitive generics market in Europe and the US, the margins of Cipla are more dependent on Indian markets and the growth of business of bulk drugs, which Cipla sells to other generic manufacturers, like Watson and Ivax.

    Going forward, we believe that Cipla will continue to deliver growth both through domestic and international operations. While the growth in topline will be robust, the history of consistency in margins suggests that the topline growth will penetrate down to the bottomline, thus increasing the shareholder value. At a P/E of 22.5x (twelve month trailing EPS), the stock is trading at a discount to Ranbaxy (24.8x) and Dr Reddy's (33.2x).

    Cipla's valuations are a little lower than its peers owing to two reasons. For one, if we take a long-term view, you have to look at the sustainability of the business. Here, Cipla may get hit because of its dependence on bulk drugs for growth which are more like commodities and the only advantage company has is its cost competitiveness which can be replicated by other companies over a period of time. Formulations business too is only in unregulated markets, and these markets will soon come under WTO purview, which might influence the company's ability to launch new products in the market. But over the short term, Cipla's business profile and prospects are more visible.

     

     

    Equitymaster requests your view! Post a comment on "Cipla vs Peers". Click here!

      
     

    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CIPLA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK CIPLA

    CIPLA - CADILA HEALTHCARE COMPARISON

    Compare Company With Charts

    COMPARE CIPLA WITH

    MARKET STATS